Linked Life Data

7577622

Source:http://linkedlifedata.com/resource/pubmed/id/7577622

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7577622rdf:typepubmed:Citationlld:pubmed
pubmed-article:7577622lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:7577622lifeskim:mentionsumls-concept:C0014822lld:lifeskim
pubmed-article:7577622lifeskim:mentionsumls-concept:C0021757lld:lifeskim
pubmed-article:7577622lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:7577622lifeskim:mentionsumls-concept:C1136335lld:lifeskim
pubmed-article:7577622lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:7577622lifeskim:mentionsumls-concept:C0205345lld:lifeskim
pubmed-article:7577622lifeskim:mentionsumls-concept:C1516960lld:lifeskim
pubmed-article:7577622pubmed:issue1lld:pubmed
pubmed-article:7577622pubmed:dateCreated1995-12-4lld:pubmed
pubmed-article:7577622pubmed:abstractTextConditions are described which promote the erythroid development of the FDCP-Mix A4 (A4) cell line with accompanying proliferation of the cells. The requirements for this development are low concentrations of interleukin 3 (IL-3) plus the presence of erythropoietin (epo) and haemin. When high concentrations of IL-3 are added with erythropoietin and haemin the cells do not differentiate and maintain their blast cell morphology. Addition of haemin, in the absence of erythropoietin, does not promote erythroid development, but the presence of haemin with erythropoietin promotes increased proliferation and maturation. The morphological maturation of A4 cells along the erythroid lineage is accompanied by a gradual loss of clonogenic potential, loss of A4 cell multipotency, increased erythropoietin receptor expression, and an increased expression of the beta-globin gene. An initial increase in mitogenic responsiveness to erythropoietin is followed by a decrease as the cells become refractory to all mitogenic stimuli with the acquisition of a postmitotic, mature erythroid cell phenotype.lld:pubmed
pubmed-article:7577622pubmed:languageenglld:pubmed
pubmed-article:7577622pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577622pubmed:citationSubsetIMlld:pubmed
pubmed-article:7577622pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577622pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577622pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577622pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577622pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577622pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577622pubmed:statusMEDLINElld:pubmed
pubmed-article:7577622pubmed:monthSeplld:pubmed
pubmed-article:7577622pubmed:issn0007-1048lld:pubmed
pubmed-article:7577622pubmed:authorpubmed-author:DexterT MTMlld:pubmed
pubmed-article:7577622pubmed:authorpubmed-author:HeyworthC MCMlld:pubmed
pubmed-article:7577622pubmed:authorpubmed-author:CrossM AMAlld:pubmed
pubmed-article:7577622pubmed:authorpubmed-author:WhettonA DADlld:pubmed
pubmed-article:7577622pubmed:authorpubmed-author:FairbairnL...lld:pubmed
pubmed-article:7577622pubmed:authorpubmed-author:AlauldinMMlld:pubmed
pubmed-article:7577622pubmed:issnTypePrintlld:pubmed
pubmed-article:7577622pubmed:volume91lld:pubmed
pubmed-article:7577622pubmed:ownerNLMlld:pubmed
pubmed-article:7577622pubmed:authorsCompleteYlld:pubmed
pubmed-article:7577622pubmed:pagination15-22lld:pubmed
pubmed-article:7577622pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:meshHeadingpubmed-meshheading:7577622-...lld:pubmed
pubmed-article:7577622pubmed:year1995lld:pubmed
pubmed-article:7577622pubmed:articleTitleErythroid development of the FDCP-Mix A4 multipotent cell line is governed by the relative concentrations of erythropoietin and interleukin 3.lld:pubmed
pubmed-article:7577622pubmed:affiliationCancer Research Campaign Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester.lld:pubmed
pubmed-article:7577622pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7577622pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7577622lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7577622lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7577622lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7577622lld:pubmed